Zhu ZhiYun – General Manager, Zambon China
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Address: 20th Floor, NCPC Building (Grand Milea Hotel), No.56 North Tiyu Street, Shijiazhuang, Hebei, P.R.China, Post Code: 050015
Tel: +86 311 85992911
Web: http://www.ncpc.com/
North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC in its early days was one of the key construction projects during the Chinese First Five-Year Plan. After five years of construction beginning in June 1953, operation commenced in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC has a history of commercial production of antibiotics in China. With 45 years of development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking as one of the Top 500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets were USD2 billion, and the company was employing 18500 staff. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of ‘Service for Life ‘, NCPC aims to build bright future for all the people.
Antibiotics, Immunosuppressants
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in…
Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large. We are a Chinese…
Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of…
Catherine Lee, general manager and managing director of West Pharmaceutical Services China, shares the highlights of her 2.5 years heading West’s China affiliate; West’s commitment to delivering their global scientific…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
See our Cookie Privacy Policy Here
